Microbiologic outcomes of ceftazidime-avibactam dosing in patients with sepsis utilizing renal replacement therapies

IF 1.2 4区医学 Q3 UROLOGY & NEPHROLOGY

Hemodialysis International Pub Date : 2023-05-05 DOI:10.1111/hdi.13090

Wasim S. El Nekidy, Mooza Al Ali, Emna Abidi, Islam M. Ghazi, Nizar Attallah, Rania El Lababidi, Mohamad Mooty, Muriel Ghosn, Jihad Mallat

{"title":"Microbiologic outcomes of ceftazidime-avibactam dosing in patients with sepsis utilizing renal replacement therapies","authors":"Wasim S. El Nekidy, Mooza Al Ali, Emna Abidi, Islam M. Ghazi, Nizar Attallah, Rania El Lababidi, Mohamad Mooty, Muriel Ghosn, Jihad Mallat","doi":"10.1111/hdi.13090","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The suggested dose of ceftazidime-avibactam (CEF/AVI) in patient with multidrug resistant organisms and utilizing renal replacement therapies (RRTs) is not validated in clinical studies. The objective of this study was to evaluate the microbiologic cure of bacteremia and pneumonia using the recommended CEF/AVI dosing in patients utilizing RRT.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective observational study conducted at our institution between September 15, 2018 and March 15, 2022. The primary end point was to determine the microbiologic cure. The secondary end points were the clinical cure, 30-day recurrence, 30-day all cause mortality.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifty-six patients met the inclusion criteria, 36 (64.3%) were males, the median age was 69 (59.5–79.3) years, and the median weight was 69 (60–83.8) kg. Pneumonia represented 34 (60.7%) of infections. Microbiologic cure was achieved in 32 (57%) subjects. However, clinical cure was achieved in 23 (71.9%) patients in the microbiologic cure group versus 12 (50%) in the microbiologic failure group (<i>p</i> = 0.094). The 30-day recurrence occurred in 2 (6.3%) patients in the microbiologic cure group versus 3 (12.5%) in the microbiologic failure group (<i>p</i> = 0.673). Further, the 30-day all-cause mortality was 18 (56.3%) versus 10 (41.7%) in both groups respectively (<i>p</i> = 0.28). The most used dose in patients utilizing continuous veno-venous hemofiltration (CVVH) was 1.25 g q8h, while the dose was 1.25 g q24h in those who utilized intermittent hemodialysis (IHD). The multivariate logistic regression indicated that bacteremia (OR 41.5 [3.77–46]), <i>Enterobacterales</i> (OR 5.4 [1.04–27.9]), and the drug daily dose (OR 2.33 [1.15–4.72]) were independently associated with microbiologic cure.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Microbiologic cure of ceftazidime-avibactam in patient utilizing CVVH and IHD is dependent on bacteremia diagnosis, the drug daily dose, and bacterial species. These findings need to be replicated in a larger prospective study, with no recommendations in those utilizing RRT.</p>\n </section>\n </div>","PeriodicalId":12815,"journal":{"name":"Hemodialysis International","volume":"27 3","pages":"289-295"},"PeriodicalIF":1.2000,"publicationDate":"2023-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hemodialysis International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hdi.13090","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The suggested dose of ceftazidime-avibactam (CEF/AVI) in patient with multidrug resistant organisms and utilizing renal replacement therapies (RRTs) is not validated in clinical studies. The objective of this study was to evaluate the microbiologic cure of bacteremia and pneumonia using the recommended CEF/AVI dosing in patients utilizing RRT.

Methods

A retrospective observational study conducted at our institution between September 15, 2018 and March 15, 2022. The primary end point was to determine the microbiologic cure. The secondary end points were the clinical cure, 30-day recurrence, 30-day all cause mortality.

Results

Fifty-six patients met the inclusion criteria, 36 (64.3%) were males, the median age was 69 (59.5–79.3) years, and the median weight was 69 (60–83.8) kg. Pneumonia represented 34 (60.7%) of infections. Microbiologic cure was achieved in 32 (57%) subjects. However, clinical cure was achieved in 23 (71.9%) patients in the microbiologic cure group versus 12 (50%) in the microbiologic failure group (p = 0.094). The 30-day recurrence occurred in 2 (6.3%) patients in the microbiologic cure group versus 3 (12.5%) in the microbiologic failure group (p = 0.673). Further, the 30-day all-cause mortality was 18 (56.3%) versus 10 (41.7%) in both groups respectively (p = 0.28). The most used dose in patients utilizing continuous veno-venous hemofiltration (CVVH) was 1.25 g q8h, while the dose was 1.25 g q24h in those who utilized intermittent hemodialysis (IHD). The multivariate logistic regression indicated that bacteremia (OR 41.5 [3.77–46]), Enterobacterales (OR 5.4 [1.04–27.9]), and the drug daily dose (OR 2.33 [1.15–4.72]) were independently associated with microbiologic cure.

Conclusion

Microbiologic cure of ceftazidime-avibactam in patient utilizing CVVH and IHD is dependent on bacteremia diagnosis, the drug daily dose, and bacterial species. These findings need to be replicated in a larger prospective study, with no recommendations in those utilizing RRT.

查看原文本刊更多论文

头孢他啶-阿维巴坦在脓毒症患者中使用肾脏替代疗法的微生物学结果

多药耐药患者使用头孢他啶-阿维巴坦(CEF/AVI)的推荐剂量和肾替代疗法(RRTs)尚未在临床研究中得到验证。本研究的目的是评估在使用RRT的患者中使用推荐的CEF/AVI剂量对菌血症和肺炎的微生物治疗效果。方法2018年9月15日至2022年3月15日在我院进行回顾性观察研究。主要目的是确定微生物治疗。次要终点为临床治愈、30天复发率、30天全因死亡率。结果56例患者符合纳入标准，其中男性36例(64.3%)，中位年龄69(59.5-79.3)岁，中位体重69 (60-83.8)kg。肺炎占34例(60.7%)。32例(57%)患者获得微生物治疗。然而，微生物治疗组有23例(71.9%)患者获得临床治愈，而微生物治疗失败组有12例(50%)患者获得临床治愈(p = 0.094)。微生物治疗组30天复发2例(6.3%)，微生物治疗失败组3例(12.5%)(p = 0.673)。此外，两组30天全因死亡率分别为18例(56.3%)和10例(41.7%)(p = 0.28)。使用连续静脉-静脉血液滤过(CVVH)的患者最多使用的剂量为1.25 g / 8h，而使用间歇血液透析(IHD)的患者最多使用的剂量为1.25 g / 24h。多因素logistic回归分析显示，菌血症(OR为41.5[3.77-46])、肠杆菌(OR为5.4[1.04-27.9])和药物日剂量(OR为2.33[1.15-4.72])与微生物治愈率独立相关。结论头孢他啶-阿维巴坦对CVVH和IHD患者的微生物治疗取决于菌血症诊断、日剂量和细菌种类。这些发现需要在更大的前瞻性研究中得到证实，对那些使用RRT的人没有建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hemodialysis International UROLOGY & NEPHROLOGY-

CiteScore

2.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hemodialysis International was originally an annual publication containing the Proceedings of the International Symposium on Hemodialysis held in conjunction with the Annual Dialysis Conference. Since 2003, Hemodialysis International is published quarterly and contains original papers on clinical and experimental topics related to dialysis in addition to the Annual Dialysis Conference supplement. This journal is a must-have for nephrologists, nurses, and technicians worldwide. Quarterly issues of Hemodialysis International are included with your membership to the International Society for Hemodialysis. The journal contains original articles, review articles, and commentary to keep readers completely updated in the field of hemodialysis. Edited by international and multidisciplinary experts, Hemodialysis International disseminates critical information in the field.